Persistent Allergic Asthma
Conditions
Keywords
omalizumab, asthma, immunoglobulin E, IgE
Brief summary
This study will assess the efficacy, safety and tolerability of omalizumab, compared to placebo in 18 to 75 year old Chinese patients with moderate to severe persistent allergic asthma who have inadequate asthma control despite treatment according to GINA (2009) Step 4 therapy.
Interventions
DRUGOmalizumab
The minimum dose of 0.016 mg/kg/IgE (IU/mL) omalizumab was administered every 4 weeks by subcutaneous injection.
DRUGPlacebo
The minimum dose of 0.016 mg/kg/IgE (IU/mL) placebo was administered every 4 weeks by subcutaneous injection.
Sponsors
Genentech, Inc.
Novartis Pharmaceuticals
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Met study drug-dosing table eligibility criteria (serum baseline total IgE level ≥ 30 to ≤ 700 IU/mL and body weight \> 20 kg and ≤ 150 kg) * Diagnosed with asthma ≥ 1 year duration at Screening, and a history of asthma that is not adequately controlled with GINA (2009) Step 4 therapy * Received medium-to-high dose inhaled corticosteroid \> 500 µg Beclomethasone Diproprionate (BDP), or equivalent plus regularly inhaled LABA, either separately or in combination, for at least 8 weeks prior to screening * Met specific asthma exacerbations eligibility criteria prior to the screening period * Exhibited inadequate symptom control as demonstrated by specific criteria (in keeping with GINA 2009 guidelines) * Positive skin prick test to at least one perennial aeroallergen documented by a historical test within 12 months prior to screening, or at Visit 1 * FEV1 ≥ 40% and \< 80% of the predicted normal value for the patient (using local standards), after withholding bronchodilators at Visit 2
Exclusion criteria
* Used other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer. For biological agent-based investigational drugs, such as monoclonal antibodies, at least six months will need to have passed between the last administration of the drug and the patient's Screening Visit. * History of malignancy * History of allergies and diseases that could interfere with the analyses * Clinically significant abnormality on a 12-lead ECG recorded at Visit 1 * Elevated IgE levels for reasons other than allergy * Current smokers, or a former smoker with a smoking history of \> 10 pack-years. A former smoker must have abstained for a minimum of 12 months before randomization * Receiving specific medications * Clinically significant laboratory abnormalities (not associated with the study indication) at Visit 1 Other protocol-defined inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Mean Morning Peak Expiratory Flow (PEF) Following the 24-week Treatment Period | Baseline, 24 weeks | A Peak Expiratory Flow (PEF) meter was distributed to patients at Visit 1, to be used to measure PEF twice-daily as directed. During the Screening and Treatment Periods, PEF was measured in the morning and evening every day. the morning PEF was performed within 15 minutes after waking, and the evening PEF approximately 12 hours later. Patients were encouraged to perform morning and evening PEF measurements before the use of any LABA or rescue medication. The highest of 3 values was recorded as the daily personal best. The personal best was used to calculate the mean morning PEF and mean evening PEF value collected between assessment Visits LS Mean of change from baseline in mean morning PEF is calculated with the ANCOVA model using treatment, stratification group, dosing schedule, gender, center grouping, smoking status, and baseline mean morning PEF as covariates. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Mean Evening PEF (L/Min) Following 24-week Treatment | Baseline, 24 weeks | A Peak Expiratory Flow (PEF) meter was distributed to patients at Visit 1, to be used to measure PEF twice-daily as directed. During the Screening and Treatment Periods, PEF was measured in the morning and evening every day. the morning PEF was performed within 15 minutes after waking, and the evening PEF approximately 12 hours later. Patients were encouraged to perform morning and evening PEF measurements before the use of any LABA or rescue medication. The highest of 3 values was recorded as the daily personal best. The personal best was used to calculate the mean morning PEF and mean evening PEF value collected between assessment Visits. LS Mean of change from baseline in mean morning PEF is calculated with the ANCOVA model using treatment, stratification group, dosing schedule, gender, center grouping, smoking status, and baseline mean morning PEF as covariates. |
| Change From Baseline in % Predicted FEV1 Following 24-week Treatment | Baseline, 24 weeks | Spirometry was used at defined time points throughout the study to assess the clinical status of patients and to capture the following variables: forced expiratory volume in one second (FEV1), FEV1 percent predicted, forced vital capacity (FVC) and the FEV1/FVC ratio. During the Screening assessment, spirometry was performed pre- and post-bronchodilator administration to assess reversibility. During the treatment period (including prerandomization assessments on Day 1), spirometry was performed after withholding bronchodilators. The results of spirometry were required to meet the ATS/ERS criteria for acceptability and repeatability. Acceptability criteria were applied before repeatability was determined. LS Mean of change from baseline in % predicted FEV1 is calculated with the ANCOVA model using treatment, stratification group, dosing schedule, gender, center grouping, smoking status, and baseline % predicted FEV1 as covariates. |
| Change From Baseline in AQLQ Score Following 24-week Treatment | 24 weeks | The standardized version of the Asthma Quality of Life Questionnaire (AQLQs)), was used to assess the patients' asthma-related quality of life. There are 32 questions in the AQLQ and they are in 4 domains (symptoms, activity limitation, emotional function and environmental exposure). Each question was answered on a 7 point scale (1-totally limited/problems all the time, 7-not at all limited/no problems). The overall AQLQ score is the mean of all 32 responses, and the individual domain scores are the means of the items in those domains (a minimum domain / overall score of 1 = Severely impaired whereas a maximum domain / overall score of 7 = not impaired at all). A positive change from baseline score indicates improvement. |
| Percentage of Patients Achieving at Least a 0.5, 1.0 or 1.5 Point Improvement From Baseline in AQLQ Overall Score Following 24-week Treatment | 24 weeks | The standardized version of the Asthma Quality of Life Questionnaire (AQLQs)), was used to assess the patients' asthma-related quality of life. There are 32 questions in the AQLQ and they are in 4 domains (symptoms, activity limitation, emotional function and environmental exposure). Each question was answered on a 7 point scale (1-totally limited/problems all the time, 7-not at all limited/no problems). The overall AQLQ score is the mean of all 32 responses, and the individual domain scores are the means of the items in those domains (a minimum domain / overall score of 1 = Severely impaired whereas a maximum domain / overall score of 7 = not impaired at all). A positive change from baseline score indicates improvement. |
| Change From Baseline in ACQ Score Following 24-week Treatment | 24 weeks | The Asthma Control Questionnaire (ACQ) is a questionnaire consisting of 7 questions assessing symptoms, airway caliber and rescue β2-agonist use. One value representing overall asthma control on that occasion was calculated. Decrease in scores of 0.5 or higher between ACQ assessments are considered clinically meaningful. The ACQ was completed by the patient at the Investigator's site at Visit 2 (Week 1, pre-dose), Visit 6 (after completion of 16 weeks of treatment) and at the End of Study/Early Termination visit. LS Mean of change from baseline in ACQ score is calculated with the ANCOVA model using treatment, stratification group, dosing schedule, center grouping, smoking status, and baseline ACQ score as covariates. Score 0= totally controlled, 6= extremely poorly controlled |
| Percentage of Patients With at Least a 0.5 or 0.75 Point Improvement in the ACQ Score at Week 24 | 24 weeks | The Asthma Control Questionnaire (ACQ) is a questionnaire consisting of 7 questions assessing symptoms, airway caliber and rescue β2-agonist use. One value representing overall asthma control on that occasion was calculated. Decrease in scores of 0.5 or higher between ACQ assessments are considered clinically meaningful. The ACQ was completed by the patient at the Investigator's site at Visit 2 (Week 1, pre-dose), Visit 6 (after completion of 16 weeks of treatment) and at the End of Study/Early Termination visit. Only patients with no more than 1 item missing are included, and the missing item was imputed by interpolation |
| Change From Baseline in Asthma Symptom Scores Following 24-week Treatment | 24 weeks | Total asthma symptom score was derived for each day as the total of the morning (scale 0-1), daytime (scale 0-4) and nocturnal (scale 0-4) scores with a max score of 9. The mean score across the 28 days prior to the week 24 assessment visit was used to calculate a change from baseline. Analysis of total asthma symptom score was performed using ANCOVA model and Van-Elteren test. LS Mean of change from baseline in mean asthma symptom score is calculated with the ANCOVA model using treatment, stratification group, dosing schedule, gender, smoking status, center grouping, and baseline mean asthma symptom scores as covariates. Decrease of score on change from baseline means improvement of asthma symptom control. |
| Percentage of Participants With Investigator and Patient Global Evaluation of Treatment Effectiveness (GETE) at Weeks 16 and 24 | 16 and 24 weeks | The global evaluation of treatment effectiveness (GETE) is an assessment of asthma symptom control and overall response to asthma treatment. The evaluation was performed by both investigator and patient, each using the same 5 point scale. The GETE scale ranges were as follows: excellent, good, moderate, poor and worsening. A good or excellent response on the 5 point scale indicated that a patient had responded to treatment. 1=excellent 2=good 3=moderate 4=poor 5= worsening. Responder is defined as the patient who achieved an excellent or good response. Non-responder isdefined as the patient who achieved a moderate or poor or worsening response. |
| Change From Baseline in Number of Puffs of Asthma Rescue Medication Following 24-week Treatment | 24 weeks | Analysis of rescue medication use followed a similar method to that employed for total asthma symptom score. The mean number of puffs across the 28 days prior to the Week 24 assessment visit was used to calculate a change from baseline. LS Mean of change from baseline in mean number of puffs of asthma rescue medication is calculated with the ANCOVA model using treatment, stratification group, dosing schedule, gender, smoking status, center grouping, and baseline mean number of puffs of asthma rescue medication as covariates. |
Countries
China
Participant flow
Recruitment details
Of the 616 patients randomized 7 (2 omalizumab and 5 placebo) did not receive drug and were excluded from the Full Analysis Set (FAS) and Safety Set.
Pre-assignment details
One additional patient did not receive study drug for greater than 60 days and was also removed from the FAS. 4 patients initially randomized to the placebo group received omalizumab at one or more administration and were considered part of the omalizumab group for the Safety Set.
Participants by arm
| Arm | Count |
|---|---|
| Omalizumab Omalizumab was supplied as lyophilized, sterile powder in a single-use, 5 mL vial that was designed to deliver 150 mg of omalizumab for subcutaneous administration upon reconstitution with 1.4 mL sterile water for injection. The minimum dose of 0.016 mg/kg/IgE (IU/mL) omalizumab was administered every 4 weeks by subcutaneous injection. | 310 |
| Placebo The placebo was the same mixture of inactive excipients, in quality and quantity, as those used for the drug product. The minimum dose of 0.016 mg/kg/IgE (IU/mL) placebo was administered every 4 weeks by subcutaneous injection. | 299 |
| Total | 609 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Administrative Probelms | 1 | 4 |
| Overall Study | Adverse Event | 3 | 3 |
| Overall Study | Death | 1 | 0 |
| Overall Study | Lack of Efficacy | 1 | 3 |
| Overall Study | Lost to Follow-up | 1 | 1 |
| Overall Study | Protocol Violation | 0 | 1 |
| Overall Study | Withdrawal by Subject | 4 | 4 |
Baseline characteristics
| Characteristic | Omalizumab | Placebo | Total |
|---|---|---|---|
| Age, Continuous | 45.8 Years STANDARD_DEVIATION 12.03 | 47.1 Years STANDARD_DEVIATION 11.64 | 46.5 Years STANDARD_DEVIATION 11.85 |
| Age, Customized 18-<65 years | 290 Participants | 285 Participants | 575 Participants |
| Age, Customized 65<=75 years | 20 Participants | 14 Participants | 34 Participants |
| Sex: Female, Male Female | 171 Participants | 157 Participants | 328 Participants |
| Sex: Female, Male Male | 139 Participants | 142 Participants | 281 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 95 / 310 | 90 / 299 |
| serious Total, serious adverse events | 8 / 310 | 11 / 299 |
Outcome results
Primary
Change From Baseline in Mean Morning Peak Expiratory Flow (PEF) Following the 24-week Treatment Period
A Peak Expiratory Flow (PEF) meter was distributed to patients at Visit 1, to be used to measure PEF twice-daily as directed. During the Screening and Treatment Periods, PEF was measured in the morning and evening every day. the morning PEF was performed within 15 minutes after waking, and the evening PEF approximately 12 hours later. Patients were encouraged to perform morning and evening PEF measurements before the use of any LABA or rescue medication. The highest of 3 values was recorded as the daily personal best. The personal best was used to calculate the mean morning PEF and mean evening PEF value collected between assessment Visits LS Mean of change from baseline in mean morning PEF is calculated with the ANCOVA model using treatment, stratification group, dosing schedule, gender, center grouping, smoking status, and baseline mean morning PEF as covariates.
Time frame: Baseline, 24 weeks
Population: The FAS consisted of all randomized patients who received at least one dose of study drug. 7 randomized patients did not receive study drug and were excluded along with 1 other patient who did not receive study drug for more than 60 days
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Omalizumab | Change From Baseline in Mean Morning Peak Expiratory Flow (PEF) Following the 24-week Treatment Period | 27.03 L/min | Standard Error 20.865 |
| Placebo | Change From Baseline in Mean Morning Peak Expiratory Flow (PEF) Following the 24-week Treatment Period | 18.18 L/min | Standard Error 21.086 |
Secondary
Change From Baseline in ACQ Score Following 24-week Treatment
The Asthma Control Questionnaire (ACQ) is a questionnaire consisting of 7 questions assessing symptoms, airway caliber and rescue β2-agonist use. One value representing overall asthma control on that occasion was calculated. Decrease in scores of 0.5 or higher between ACQ assessments are considered clinically meaningful. The ACQ was completed by the patient at the Investigator's site at Visit 2 (Week 1, pre-dose), Visit 6 (after completion of 16 weeks of treatment) and at the End of Study/Early Termination visit. LS Mean of change from baseline in ACQ score is calculated with the ANCOVA model using treatment, stratification group, dosing schedule, center grouping, smoking status, and baseline ACQ score as covariates. Score 0= totally controlled, 6= extremely poorly controlled
Time frame: 24 weeks
Population: The FAS consisted of all randomized patients who received at least one dose of study drug. 7 randomized patients did not receive study drug and were excluded along with 1 other patient who did not receive study drug for more than 60 days
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Omalizumab | Change From Baseline in ACQ Score Following 24-week Treatment | -0.51 Units on a scale | Standard Error 0.092 |
| Placebo | Change From Baseline in ACQ Score Following 24-week Treatment | -0.34 Units on a scale | Standard Error 0.091 |
Secondary
Change From Baseline in AQLQ Score Following 24-week Treatment
The standardized version of the Asthma Quality of Life Questionnaire (AQLQs)), was used to assess the patients' asthma-related quality of life. There are 32 questions in the AQLQ and they are in 4 domains (symptoms, activity limitation, emotional function and environmental exposure). Each question was answered on a 7 point scale (1-totally limited/problems all the time, 7-not at all limited/no problems). The overall AQLQ score is the mean of all 32 responses, and the individual domain scores are the means of the items in those domains (a minimum domain / overall score of 1 = Severely impaired whereas a maximum domain / overall score of 7 = not impaired at all). A positive change from baseline score indicates improvement.
Time frame: 24 weeks
Population: The FAS consisted of all randomized patients who received at least one dose of study drug. 7 randomized patients did not receive study drug and were excluded along with 1 other patient who did not receive study drug for more than 60 days
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Omalizumab | Change From Baseline in AQLQ Score Following 24-week Treatment | Symptom Score (n=208,206) | 0.47 Units on a scale | Standard Error 0.143 |
| Omalizumab | Change From Baseline in AQLQ Score Following 24-week Treatment | Emotions Score (n=217,213) | 0.64 Units on a scale | Standard Error 0.184 |
| Omalizumab | Change From Baseline in AQLQ Score Following 24-week Treatment | Activity Score (n=203,198) | 0.46 Units on a scale | Standard Error 0.133 |
| Omalizumab | Change From Baseline in AQLQ Score Following 24-week Treatment | Environmental Score (n=201,203) | 0.54 Units on a scale | Standard Error 0.199 |
| Omalizumab | Change From Baseline in AQLQ Score Following 24-week Treatment | Overall Score (n=182,178) | 0.51 Units on a scale | Standard Error 0.155 |
| Placebo | Change From Baseline in AQLQ Score Following 24-week Treatment | Environmental Score (n=201,203) | 0.17 Units on a scale | Standard Error 0.199 |
| Placebo | Change From Baseline in AQLQ Score Following 24-week Treatment | Overall Score (n=182,178) | 0.10 Units on a scale | Standard Error 0.155 |
| Placebo | Change From Baseline in AQLQ Score Following 24-week Treatment | Symptom Score (n=208,206) | 0.18 Units on a scale | Standard Error 0.142 |
| Placebo | Change From Baseline in AQLQ Score Following 24-week Treatment | Activity Score (n=203,198) | 0.17 Units on a scale | Standard Error 0.131 |
| Placebo | Change From Baseline in AQLQ Score Following 24-week Treatment | Emotions Score (n=217,213) | 0.36 Units on a scale | Standard Error 0.181 |
Secondary
Change From Baseline in Asthma Symptom Scores Following 24-week Treatment
Total asthma symptom score was derived for each day as the total of the morning (scale 0-1), daytime (scale 0-4) and nocturnal (scale 0-4) scores with a max score of 9. The mean score across the 28 days prior to the week 24 assessment visit was used to calculate a change from baseline. Analysis of total asthma symptom score was performed using ANCOVA model and Van-Elteren test. LS Mean of change from baseline in mean asthma symptom score is calculated with the ANCOVA model using treatment, stratification group, dosing schedule, gender, smoking status, center grouping, and baseline mean asthma symptom scores as covariates. Decrease of score on change from baseline means improvement of asthma symptom control.
Time frame: 24 weeks
Population: The FAS consisted of all randomized patients who received at least one dose of study drug. 7 randomized patients did not receive study drug and were excluded along with 1 other patient who did not receive study drug for more than 60 days
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Omalizumab | Change From Baseline in Asthma Symptom Scores Following 24-week Treatment | Total symptom score (n=287,282) | -1.65 Units on a scale | Standard Error 0.462 |
| Omalizumab | Change From Baseline in Asthma Symptom Scores Following 24-week Treatment | Night-time symptom (n=292,288) | -0.67 Units on a scale | Standard Error 0.203 |
| Omalizumab | Change From Baseline in Asthma Symptom Scores Following 24-week Treatment | Morning symptom (n=292,288) | -0.21 Units on a scale | Standard Error 0.089 |
| Omalizumab | Change From Baseline in Asthma Symptom Scores Following 24-week Treatment | Daytime symptom (n=292,288) | -0.79 Units on a scale | Standard Error 0.246 |
| Placebo | Change From Baseline in Asthma Symptom Scores Following 24-week Treatment | Daytime symptom (n=292,288) | -0.72 Units on a scale | Standard Error 0.248 |
| Placebo | Change From Baseline in Asthma Symptom Scores Following 24-week Treatment | Total symptom score (n=287,282) | -1.44 Units on a scale | Standard Error 0.466 |
| Placebo | Change From Baseline in Asthma Symptom Scores Following 24-week Treatment | Morning symptom (n=292,288) | -0.20 Units on a scale | Standard Error 0.09 |
| Placebo | Change From Baseline in Asthma Symptom Scores Following 24-week Treatment | Night-time symptom (n=292,288) | -0.55 Units on a scale | Standard Error 0.205 |
Secondary
Change From Baseline in Mean Evening PEF (L/Min) Following 24-week Treatment
A Peak Expiratory Flow (PEF) meter was distributed to patients at Visit 1, to be used to measure PEF twice-daily as directed. During the Screening and Treatment Periods, PEF was measured in the morning and evening every day. the morning PEF was performed within 15 minutes after waking, and the evening PEF approximately 12 hours later. Patients were encouraged to perform morning and evening PEF measurements before the use of any LABA or rescue medication. The highest of 3 values was recorded as the daily personal best. The personal best was used to calculate the mean morning PEF and mean evening PEF value collected between assessment Visits. LS Mean of change from baseline in mean morning PEF is calculated with the ANCOVA model using treatment, stratification group, dosing schedule, gender, center grouping, smoking status, and baseline mean morning PEF as covariates.
Time frame: Baseline, 24 weeks
Population: The FAS consisted of all randomized patients who received at least one dose of study drug. 7 randomized patients did not receive study drug and were excluded along with 1 other patient who did not receive study drug for more than 60 days
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Omalizumab | Change From Baseline in Mean Evening PEF (L/Min) Following 24-week Treatment | 22.96 L/min | Standard Error 20.145 |
| Placebo | Change From Baseline in Mean Evening PEF (L/Min) Following 24-week Treatment | 15.53 L/min | Standard Error 20.35 |
Secondary
Change From Baseline in Number of Puffs of Asthma Rescue Medication Following 24-week Treatment
Analysis of rescue medication use followed a similar method to that employed for total asthma symptom score. The mean number of puffs across the 28 days prior to the Week 24 assessment visit was used to calculate a change from baseline. LS Mean of change from baseline in mean number of puffs of asthma rescue medication is calculated with the ANCOVA model using treatment, stratification group, dosing schedule, gender, smoking status, center grouping, and baseline mean number of puffs of asthma rescue medication as covariates.
Time frame: 24 weeks
Population: The FAS consisted of all randomized patients who received at least one dose of study drug. 7 randomized patients did not receive study drug and were excluded along with 1 other patient who did not receive study drug for more than 60 days
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Omalizumab | Change From Baseline in Number of Puffs of Asthma Rescue Medication Following 24-week Treatment | Daily number of puffs (n=296,291) | -1.14 Number of puffs | Standard Error 0.566 |
| Omalizumab | Change From Baseline in Number of Puffs of Asthma Rescue Medication Following 24-week Treatment | Daytime number of puffs (n=292-289) | -0.53 Number of puffs | Standard Error 0.301 |
| Omalizumab | Change From Baseline in Number of Puffs of Asthma Rescue Medication Following 24-week Treatment | Nighttime number of puffs (n=292-289) | -0.56 Number of puffs | Standard Error 0.276 |
| Placebo | Change From Baseline in Number of Puffs of Asthma Rescue Medication Following 24-week Treatment | Daily number of puffs (n=296,291) | -0.85 Number of puffs | Standard Error 0.572 |
| Placebo | Change From Baseline in Number of Puffs of Asthma Rescue Medication Following 24-week Treatment | Daytime number of puffs (n=292-289) | -0.38 Number of puffs | Standard Error 0.304 |
| Placebo | Change From Baseline in Number of Puffs of Asthma Rescue Medication Following 24-week Treatment | Nighttime number of puffs (n=292-289) | -0.42 Number of puffs | Standard Error 0.279 |
Secondary
Change From Baseline in % Predicted FEV1 Following 24-week Treatment
Spirometry was used at defined time points throughout the study to assess the clinical status of patients and to capture the following variables: forced expiratory volume in one second (FEV1), FEV1 percent predicted, forced vital capacity (FVC) and the FEV1/FVC ratio. During the Screening assessment, spirometry was performed pre- and post-bronchodilator administration to assess reversibility. During the treatment period (including prerandomization assessments on Day 1), spirometry was performed after withholding bronchodilators. The results of spirometry were required to meet the ATS/ERS criteria for acceptability and repeatability. Acceptability criteria were applied before repeatability was determined. LS Mean of change from baseline in % predicted FEV1 is calculated with the ANCOVA model using treatment, stratification group, dosing schedule, gender, center grouping, smoking status, and baseline % predicted FEV1 as covariates.
Time frame: Baseline, 24 weeks
Population: The FAS consisted of all randomized patients who received at least one dose of study drug. 7 randomized patients did not receive study drug and were excluded along with 1 other patient who did not receive study drug for more than 60 days
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Omalizumab | Change From Baseline in % Predicted FEV1 Following 24-week Treatment | 19.113 L/min | Standard Error 5.613 |
| Placebo | Change From Baseline in % Predicted FEV1 Following 24-week Treatment | 14.989 L/min | Standard Error 5.6645 |
Secondary
Percentage of Participants With Investigator and Patient Global Evaluation of Treatment Effectiveness (GETE) at Weeks 16 and 24
The global evaluation of treatment effectiveness (GETE) is an assessment of asthma symptom control and overall response to asthma treatment. The evaluation was performed by both investigator and patient, each using the same 5 point scale. The GETE scale ranges were as follows: excellent, good, moderate, poor and worsening. A good or excellent response on the 5 point scale indicated that a patient had responded to treatment. 1=excellent 2=good 3=moderate 4=poor 5= worsening. Responder is defined as the patient who achieved an excellent or good response. Non-responder isdefined as the patient who achieved a moderate or poor or worsening response.
Time frame: 16 and 24 weeks
Population: The FAS consisted of all randomized patients who received at least one dose of study drug. 7 randomized patients did not receive study drug and were excluded along with 1 other patient who did not receive study drug for more than 60 days
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Omalizumab | Percentage of Participants With Investigator and Patient Global Evaluation of Treatment Effectiveness (GETE) at Weeks 16 and 24 | Week 24 Investigator missing | 3.3 Percent |
| Omalizumab | Percentage of Participants With Investigator and Patient Global Evaluation of Treatment Effectiveness (GETE) at Weeks 16 and 24 | Week 16 Investigator non-responder | 25.5 Percent |
| Omalizumab | Percentage of Participants With Investigator and Patient Global Evaluation of Treatment Effectiveness (GETE) at Weeks 16 and 24 | Week 24 Patient non-responder | 24.8 Percent |
| Omalizumab | Percentage of Participants With Investigator and Patient Global Evaluation of Treatment Effectiveness (GETE) at Weeks 16 and 24 | Week 16 Investigator missing | 2.6 Percent |
| Omalizumab | Percentage of Participants With Investigator and Patient Global Evaluation of Treatment Effectiveness (GETE) at Weeks 16 and 24 | Week 24 Patient Missing | 3.3 Percent |
| Omalizumab | Percentage of Participants With Investigator and Patient Global Evaluation of Treatment Effectiveness (GETE) at Weeks 16 and 24 | Week 16 Patient responder | 70.6 Percent |
| Omalizumab | Percentage of Participants With Investigator and Patient Global Evaluation of Treatment Effectiveness (GETE) at Weeks 16 and 24 | Week 24 Investigator non-responder | 26.5 Percent |
| Omalizumab | Percentage of Participants With Investigator and Patient Global Evaluation of Treatment Effectiveness (GETE) at Weeks 16 and 24 | Week 16 Patient non-responder | 26.8 Percent |
| Omalizumab | Percentage of Participants With Investigator and Patient Global Evaluation of Treatment Effectiveness (GETE) at Weeks 16 and 24 | Week 24 Patient responder | 71.9 Percent |
| Omalizumab | Percentage of Participants With Investigator and Patient Global Evaluation of Treatment Effectiveness (GETE) at Weeks 16 and 24 | Week 16 Patient Missing | 2.6 Percent |
| Omalizumab | Percentage of Participants With Investigator and Patient Global Evaluation of Treatment Effectiveness (GETE) at Weeks 16 and 24 | Week 16 Investigator responder | 71.9 Percent |
| Omalizumab | Percentage of Participants With Investigator and Patient Global Evaluation of Treatment Effectiveness (GETE) at Weeks 16 and 24 | Week 24 Investigator responder | 70.3 Percent |
| Placebo | Percentage of Participants With Investigator and Patient Global Evaluation of Treatment Effectiveness (GETE) at Weeks 16 and 24 | Week 16 Investigator responder | 52.3 Percent |
| Placebo | Percentage of Participants With Investigator and Patient Global Evaluation of Treatment Effectiveness (GETE) at Weeks 16 and 24 | Week 24 Investigator non-responder | 45.7 Percent |
| Placebo | Percentage of Participants With Investigator and Patient Global Evaluation of Treatment Effectiveness (GETE) at Weeks 16 and 24 | Week 24 Investigator missing | 3.6 Percent |
| Placebo | Percentage of Participants With Investigator and Patient Global Evaluation of Treatment Effectiveness (GETE) at Weeks 16 and 24 | Week 24 Patient responder | 61.6 Percent |
| Placebo | Percentage of Participants With Investigator and Patient Global Evaluation of Treatment Effectiveness (GETE) at Weeks 16 and 24 | Week 24 Patient non-responder | 34.8 Percent |
| Placebo | Percentage of Participants With Investigator and Patient Global Evaluation of Treatment Effectiveness (GETE) at Weeks 16 and 24 | Week 24 Patient Missing | 3.6 Percent |
| Placebo | Percentage of Participants With Investigator and Patient Global Evaluation of Treatment Effectiveness (GETE) at Weeks 16 and 24 | Week 24 Investigator responder | 50.7 Percent |
| Placebo | Percentage of Participants With Investigator and Patient Global Evaluation of Treatment Effectiveness (GETE) at Weeks 16 and 24 | Week 16 Investigator non-responder | 44.4 Percent |
| Placebo | Percentage of Participants With Investigator and Patient Global Evaluation of Treatment Effectiveness (GETE) at Weeks 16 and 24 | Week 16 Investigator missing | 3.3 Percent |
| Placebo | Percentage of Participants With Investigator and Patient Global Evaluation of Treatment Effectiveness (GETE) at Weeks 16 and 24 | Week 16 Patient responder | 59.6 Percent |
| Placebo | Percentage of Participants With Investigator and Patient Global Evaluation of Treatment Effectiveness (GETE) at Weeks 16 and 24 | Week 16 Patient non-responder | 37.1 Percent |
| Placebo | Percentage of Participants With Investigator and Patient Global Evaluation of Treatment Effectiveness (GETE) at Weeks 16 and 24 | Week 16 Patient Missing | 3.3 Percent |
Secondary
Percentage of Patients Achieving at Least a 0.5, 1.0 or 1.5 Point Improvement From Baseline in AQLQ Overall Score Following 24-week Treatment
The standardized version of the Asthma Quality of Life Questionnaire (AQLQs)), was used to assess the patients' asthma-related quality of life. There are 32 questions in the AQLQ and they are in 4 domains (symptoms, activity limitation, emotional function and environmental exposure). Each question was answered on a 7 point scale (1-totally limited/problems all the time, 7-not at all limited/no problems). The overall AQLQ score is the mean of all 32 responses, and the individual domain scores are the means of the items in those domains (a minimum domain / overall score of 1 = Severely impaired whereas a maximum domain / overall score of 7 = not impaired at all). A positive change from baseline score indicates improvement.
Time frame: 24 weeks
Population: The FAS consisted of all randomized patients who received at least one dose of study drug. 7 randomized patients did not receive study drug and were excluded along with 1 other patient who did not receive study drug for more than 60 days
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Omalizumab | Percentage of Patients Achieving at Least a 0.5, 1.0 or 1.5 Point Improvement From Baseline in AQLQ Overall Score Following 24-week Treatment | >=0.5 to <1.0 | 12.1 Percent |
| Omalizumab | Percentage of Patients Achieving at Least a 0.5, 1.0 or 1.5 Point Improvement From Baseline in AQLQ Overall Score Following 24-week Treatment | >=1.0 to <1.5 | 9.2 Percent |
| Omalizumab | Percentage of Patients Achieving at Least a 0.5, 1.0 or 1.5 Point Improvement From Baseline in AQLQ Overall Score Following 24-week Treatment | >=1.5 | 13.4 Percent |
| Omalizumab | Percentage of Patients Achieving at Least a 0.5, 1.0 or 1.5 Point Improvement From Baseline in AQLQ Overall Score Following 24-week Treatment | Missing | 40.5 Percent |
| Placebo | Percentage of Patients Achieving at Least a 0.5, 1.0 or 1.5 Point Improvement From Baseline in AQLQ Overall Score Following 24-week Treatment | Missing | 41.1 Percent |
| Placebo | Percentage of Patients Achieving at Least a 0.5, 1.0 or 1.5 Point Improvement From Baseline in AQLQ Overall Score Following 24-week Treatment | >=0.5 to <1.0 | 10.6 Percent |
| Placebo | Percentage of Patients Achieving at Least a 0.5, 1.0 or 1.5 Point Improvement From Baseline in AQLQ Overall Score Following 24-week Treatment | >=1.5 | 6.0 Percent |
| Placebo | Percentage of Patients Achieving at Least a 0.5, 1.0 or 1.5 Point Improvement From Baseline in AQLQ Overall Score Following 24-week Treatment | >=1.0 to <1.5 | 6.6 Percent |
Secondary
Percentage of Patients With at Least a 0.5 or 0.75 Point Improvement in the ACQ Score at Week 24
The Asthma Control Questionnaire (ACQ) is a questionnaire consisting of 7 questions assessing symptoms, airway caliber and rescue β2-agonist use. One value representing overall asthma control on that occasion was calculated. Decrease in scores of 0.5 or higher between ACQ assessments are considered clinically meaningful. The ACQ was completed by the patient at the Investigator's site at Visit 2 (Week 1, pre-dose), Visit 6 (after completion of 16 weeks of treatment) and at the End of Study/Early Termination visit. Only patients with no more than 1 item missing are included, and the missing item was imputed by interpolation
Time frame: 24 weeks
Population: The FAS consisted of all randomized patients who received at least one dose of study drug. 7 randomized patients did not receive study drug and were excluded along with 1 other patient who did not receive study drug for more than 60 days
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Omalizumab | Percentage of Patients With at Least a 0.5 or 0.75 Point Improvement in the ACQ Score at Week 24 | > -0.5 ACQ improvement | 34.6 Percent |
| Omalizumab | Percentage of Patients With at Least a 0.5 or 0.75 Point Improvement in the ACQ Score at Week 24 | > -0.75 ACQ improvement | 45.1 Percent |
| Omalizumab | Percentage of Patients With at Least a 0.5 or 0.75 Point Improvement in the ACQ Score at Week 24 | <= -0.75 ACQ improvement | 23.5 Percent |
| Omalizumab | Percentage of Patients With at Least a 0.5 or 0.75 Point Improvement in the ACQ Score at Week 24 | Missing | 31.4 Percent |
| Omalizumab | Percentage of Patients With at Least a 0.5 or 0.75 Point Improvement in the ACQ Score at Week 24 | <= -0.5 ACQ improvement | 34 Percent |
| Placebo | Percentage of Patients With at Least a 0.5 or 0.75 Point Improvement in the ACQ Score at Week 24 | Missing | 30.1 Percent |
| Placebo | Percentage of Patients With at Least a 0.5 or 0.75 Point Improvement in the ACQ Score at Week 24 | <= -0.5 ACQ improvement | 24.8 Percent |
| Placebo | Percentage of Patients With at Least a 0.5 or 0.75 Point Improvement in the ACQ Score at Week 24 | > -0.5 ACQ improvement | 45.0 Percent |
| Placebo | Percentage of Patients With at Least a 0.5 or 0.75 Point Improvement in the ACQ Score at Week 24 | <= -0.75 ACQ improvement | 15.2 Percent |
| Placebo | Percentage of Patients With at Least a 0.5 or 0.75 Point Improvement in the ACQ Score at Week 24 | > -0.75 ACQ improvement | 54.6 Percent |